Who are High dose ultra short Primaquine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tafenoquine prophylaxis, PQ unsupervised, Unsupervised primaquine treatment, PQ supervised, Supervised primaquine treatment, PQ (0.75).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-dose-ultra-short-primaquine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

High dose ultra short Primaquine — Competitive Intelligence Brief

High dose ultra short Primaquine (High dose ultra short Primaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 8-aminoquinoline antimalarial. Area: Infectious Disease.

phase 3 8-aminoquinoline antimalarial Malaria parasite (Plasmodium spp.) — mechanism involves oxidative stress generation Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

High dose ultra short Primaquine (High dose ultra short Primaquine) — Menzies School of Health Research. High-dose ultra-short primaquine rapidly eliminates malaria parasites, particularly gametocytes, to prevent transmission and treat infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
High dose ultra short Primaquine TARGET	High dose ultra short Primaquine	Menzies School of Health Research	phase 3	8-aminoquinoline antimalarial	Malaria parasite (Plasmodium spp.) — mechanism involves oxidative stress generation
Tafenoquine prophylaxis	Tafenoquine prophylaxis	Naval Medical Research Center	marketed	8-aminoquinoline antimalarial	Plasmodium mitochondrial electron transport chain
PQ unsupervised	PQ unsupervised	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium hypnozoite mitochondria
Unsupervised primaquine treatment	Unsupervised primaquine treatment	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Malaria parasite mitochondria and DNA (indirect via oxidative stress)
PQ supervised	PQ supervised	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium hypnozoites (mechanism not fully elucidated at molecular level)
Supervised primaquine treatment	Supervised primaquine treatment	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium parasite mitochondria and DNA
PQ (0.75)	PQ (0.75)	London School of Hygiene and Tropical Medicine	phase 3	8-aminoquinoline antimalarial	Plasmodium hypnozoite (liver stage parasite)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (8-aminoquinoline antimalarial class)

Menzies School of Health Research · 5 drugs in this class
London School of Hygiene and Tropical Medicine · 2 drugs in this class
Naval Medical Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High dose ultra short Primaquine — Competitive Intelligence Brief. https://druglandscape.com/ci/high-dose-ultra-short-primaquine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab